HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Corbus Pharmaceuticals (NASDAQ:CRBP) and maintained a price target of $80.
August 06, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Corbus Pharmaceuticals and maintained a price target of $80.
The reiteration of a Buy rating and a high price target of $80 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100